295 related articles for article (PubMed ID: 22382618)
21. Pinhole imaging of 131I-metaiodobenzylguanidine (131I-MIBG) in an animal model of neuroblastoma.
Accorsi R; Morowitz MJ; Charron M; Maris JM
Pediatr Radiol; 2003 Oct; 33(10):688-92. PubMed ID: 12908090
[TBL] [Abstract][Full Text] [Related]
22. Radiolabeled (4-Fluoro-3-Iodobenzyl)Guanidine Improves Imaging and Targeted Radionuclide Therapy of Norepinephrine Transporter-Expressing Tumors.
Yamaguchi A; Hanaoka H; Higuchi T; Tsushima Y
J Nucl Med; 2018 May; 59(5):815-821. PubMed ID: 29217738
[No Abstract] [Full Text] [Related]
23. Nothing but NET: a review of norepinephrine transporter expression and efficacy of 131I-mIBG therapy.
Streby KA; Shah N; Ranalli MA; Kunkler A; Cripe TP
Pediatr Blood Cancer; 2015 Jan; 62(1):5-11. PubMed ID: 25175627
[TBL] [Abstract][Full Text] [Related]
24. Feasibility of dosimetry-based high-dose 131I-meta-iodobenzylguanidine with topotecan as a radiosensitizer in children with metastatic neuroblastoma.
Gaze MN; Chang YC; Flux GD; Mairs RJ; Saran FH; Meller ST
Cancer Biother Radiopharm; 2005 Apr; 20(2):195-9. PubMed ID: 15869455
[TBL] [Abstract][Full Text] [Related]
25. Neuroblastoma imaging using a combined CT scanner-scintillation camera and 131I-MIBG.
Tang HR; Da Silva AJ; Matthay KK; Price DC; Huberty JP; Hawkins RA; Hasegawa BH
J Nucl Med; 2001 Feb; 42(2):237-47. PubMed ID: 11216522
[TBL] [Abstract][Full Text] [Related]
26. Biodistribution and Dosimetry of
Pandit-Taskar N; Zanzonico P; Staton KD; Carrasquillo JA; Reidy-Lagunes D; Lyashchenko S; Burnazi E; Zhang H; Lewis JS; Blasberg R; Larson SM; Weber WA; Modak S
J Nucl Med; 2018 Jan; 59(1):147-153. PubMed ID: 28705916
[No Abstract] [Full Text] [Related]
27. [
Pauwels E; Celen S; Baete K; Koole M; Bechter O; Bex M; Renard M; Clement PM; Jentjens S; Serdons K; Van Laere K; Bormans G; Deroose CM
Eur J Nucl Med Mol Imaging; 2023 Mar; 50(4):1134-1145. PubMed ID: 36435928
[TBL] [Abstract][Full Text] [Related]
28.
Kitamura Y; Baba S; Isoda T; Maruoka Y; Sasaki M; Kamitani T; Koga Y; Kawakubo N; Matsuura T; Ishigami K
Ann Nucl Med; 2021 May; 35(5):549-556. PubMed ID: 33586098
[TBL] [Abstract][Full Text] [Related]
29. Treatment planning for 131I-mIBG radiotherapy of neural crest tumours using 124I-mIBG positron emission tomography.
Ott RJ; Tait D; Flower MA; Babich JW; Lambrecht RM
Br J Radiol; 1992 Sep; 65(777):787-91. PubMed ID: 1393416
[TBL] [Abstract][Full Text] [Related]
30. Diagnostic value of 18F-FDG PET/CT in paediatric neuroblastoma: comparison with 131I-MIBG scintigraphy.
Dhull VS; Sharma P; Patel C; Kundu P; Agarwala S; Bakhshi S; Bhatnagar V; Bal C; Kumar R
Nucl Med Commun; 2015 Oct; 36(10):1007-13. PubMed ID: 26049371
[TBL] [Abstract][Full Text] [Related]
31. [
Samim A; Blom T; Poot AJ; Windhorst AD; Fiocco M; Tolboom N; Braat AJAT; Viol SLM; van Rooij R; van Noesel MM; Lam MGEH; Tytgat GAM; de Keizer B
Eur J Nucl Med Mol Imaging; 2023 Mar; 50(4):1146-1157. PubMed ID: 36504277
[TBL] [Abstract][Full Text] [Related]
32. Whole-body dosimetry for individualized treatment planning of 131I-MIBG radionuclide therapy for neuroblastoma.
Buckley SE; Chittenden SJ; Saran FH; Meller ST; Flux GD
J Nucl Med; 2009 Sep; 50(9):1518-24. PubMed ID: 19713562
[TBL] [Abstract][Full Text] [Related]
33. Local delivery of (131)I-MIBG to treat peritoneal neuroblastoma.
Kinuya S; Li XF; Yokoyama K; Mori H; Shiba K; Watanabe N; Shuke N; Bunko H; Michigishi T; Tonami N
Eur J Nucl Med Mol Imaging; 2003 Sep; 30(9):1246-50. PubMed ID: 12811531
[TBL] [Abstract][Full Text] [Related]
34. In vivo imaging and quantitation of adoptively transferred human antigen-specific T cells transduced to express a human norepinephrine transporter gene.
Doubrovin MM; Doubrovina ES; Zanzonico P; Sadelain M; Larson SM; O'Reilly RJ
Cancer Res; 2007 Dec; 67(24):11959-69. PubMed ID: 18089827
[TBL] [Abstract][Full Text] [Related]
35. Current concepts on the diagnostic use of MIBG in children.
Shulkin BL; Shapiro B
J Nucl Med; 1998 Apr; 39(4):679-88. PubMed ID: 9544682
[TBL] [Abstract][Full Text] [Related]
36. Enhanced tumour uptake and in vitro radiotoxicity of no-carrier-added [131I]meta-iodobenzylguanidine: implications for the targeted radiotherapy of neuroblastoma.
Mairs RJ; Russell J; Cunningham S; O'Donoghue JA; Gaze MN; Owens J; Vaidyanathan G; Zalutsky MR
Eur J Cancer; 1995; 31A(4):576-81. PubMed ID: 7576972
[TBL] [Abstract][Full Text] [Related]
37. Pediatric 131I-MIBG Therapy for Neuroblastoma: Whole-Body 131I-MIBG Clearance, Radiation Doses to Patients, Family Caregivers, Medical Staff, and Radiation Safety Measures.
Willegaignon J; Crema KP; Oliveira NC; Pelissoni RA; Coura-Filho GB; Sapienza MT; Buchpiguel CA
Clin Nucl Med; 2018 Aug; 43(8):572-578. PubMed ID: 29916922
[TBL] [Abstract][Full Text] [Related]
38. [
Wang P; Li T; Liu Z; Jin M; Su Y; Zhang J; Jing H; Zhuang H; Li F
Eur J Nucl Med Mol Imaging; 2023 Aug; 50(10):3097-3106. PubMed ID: 37160439
[TBL] [Abstract][Full Text] [Related]
39. Meta-iodobenzylguanidine scintigraphy in neuroblastoma--a comparison with conventional X-ray and ultrasound.
Müller-Gärtner HW; Erttmann R; Helmke K
Pediatr Hematol Oncol; 1986; 3(2):97-109. PubMed ID: 3153232
[TBL] [Abstract][Full Text] [Related]
40. Diagnosis and treatment of neuroblastoma using 131I-meta-iodobenzylguanidine.
Edeling CJ; Büchler Frederiksen P; Kamper J; Jeppesen P
Nuklearmedizin; 1986 Oct; 25(5):172-5. PubMed ID: 3797256
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]